Wikisage, the free encyclopedia of the second generation, is digital heritage
Mepolizumab: Difference between revisions
Jump to navigation
Jump to search
(Created page with "'''Mepolizumab''' is a humanized monoclonal antibody to interleukin-5 (IL-5) which leads to a decrease in production and maturation of eosinophils and results in a reduction i...") |
(→Links) |
||
Line 1: | Line 1: | ||
'''Mepolizumab''' is a humanized monoclonal antibody to interleukin-5 (IL-5) which leads to a decrease in production and maturation of eosinophils and results in a reduction in allergic symptoms of asthma and hypereosinophilic síndromes <ref>[https://www.ncbi.nlm.nih.gov/books/NBK548052/ LiberTox: Clinical and Research Information on Drug-Induced Liver Injury] <nowiki>[Internet]</nowiki>.</ref> | '''Mepolizumab''' is a humanized monoclonal antibody to interleukin-5 (IL-5) which leads to a decrease in production and maturation of eosinophils and results in a reduction in allergic symptoms of asthma and hypereosinophilic síndromes <ref>[https://www.ncbi.nlm.nih.gov/books/NBK548052/ LiberTox: Clinical and Research Information on Drug-Induced Liver Injury] <nowiki>[Internet]</nowiki>.</ref> | ||
==Links== | ==Links== | ||
[[Churg-Strauss_syndrome|Churg Strauss syndrome]] | |||
[https://karmel.miraheze.org/wiki/Mepolizumab karmel(miraheze):Mepolizumab] | [https://karmel.miraheze.org/wiki/Mepolizumab karmel(miraheze):Mepolizumab] | ||
<references/> | <references/> |
Revision as of 14:03, 21 December 2019
Mepolizumab is a humanized monoclonal antibody to interleukin-5 (IL-5) which leads to a decrease in production and maturation of eosinophils and results in a reduction in allergic symptoms of asthma and hypereosinophilic síndromes [1]
Links